THE INTERFACE — INSIGHTS

Perspective from the halocline.

Short, practical notes on bringing instrumentation to market — whether through services or direct equipment sales.

KOL Liaison

Why KOL adoption differs for IVD versus analytical instruments

Adoption dynamics for in-vitro diagnostics and analytical instruments look similar on paper but behave very differently in market. IVD adoption is driven by clinical utility and laboratory workflow integration, with KOLs acting as clinical advocates whose endorsement cascades through hospital networks. Analytical instruments, by contrast, are more often procurement-led and specification-driven, with KOLs influencing specification rather than approving adoption outright. Understanding which lever your platform pulls — clinical advocacy or technical specification — determines where the earliest, highest-leverage introductions should be made and how the commercial narrative should be built.

Halocline Strategic15 Jul 2026

Market Strategy

Positioning a service-led instrument launch

When an instrumentation offering reaches market as a service rather than capital equipment, the temptation is to sell the science. But service-led buyers are buying outcomes and continuity, not specifications. Positioning must reframe the offering around the problem it removes from the lab or clinic, the risk it de-risks, and the partnership model that sustains it. The critical commercial path is pilot-to-partnership conversion, and the messaging should be built to carry a prospect through each stage-gate — from reference site to multi-year agreement — without losing the thread of why they started.

Halocline Strategic1 Jul 2026

Market Strategy

When total cost of ownership beats specifications

Mature instrumentation markets frequently commoditise around specifications, and incumbents lose share to lower-cost entrants who compete on a feature checklist. The defence is rarely more features — it is reframing the buying decision around total cost of ownership, service continuity, and the hidden cost of switching. Procurement teams respond to evidence-led TCO narratives far better than to specification wars, and rebuilding the commercial story around lifetime value re-establishes the conditions for premium pricing on flagship platforms.

Halocline Strategic15 Jun 2026

Transition

The pilot that never becomes a partnership

Many service-led instrumentation companies run successful pilots that never convert into commercial agreements. The failure is rarely the science — it is the absence of a defined conversion path built into the pilot itself. A well-designed pilot has a stage-gate, a success criterion agreed up front, a named commercial owner, and a KOL advocacy thread running through it. Without those elements the pilot becomes a free demonstration, and the relationship stalls at the exact moment it should accelerate into a partnership.

Halocline Strategic1 Jun 2026
Discuss your route to market